1. Фадеев В.В., Абрамова Н.А., Прокофьев С.А., Гитель Е.П., Мельниченко Г.А, Дедов И.И. Антитела к рецептору ТТГ в дифференциальной диагностике токсического зоба. Проблемы эндокринологии. 2005; 51(4): 10 - 18. doi: 10.14341/probl200551410-18

2. Свириденко Н.Ю., Лихванцева В.Г., Беловалова И.М., Шеремета М.С., Табеева К.И. Антитела к рецептору ТТГ как предикторы тяжести и исходов эндокринной офтальмопатии у пациентов с болезнью Грейвса. Проблемы эндокринологии. 2011; 2: 23 - 26. doi: 10.14341/probl201157223-26

3. Smith TJ, Hegedus L. Graves' disease. N Engl J Med. 2016; 375: 1552 - 1565. doi: 10.1056/NEJMra1510030

4. Дедов И.И., Мельниченко Г.А., Фадеев В.В. Эндокринология. М.: ГЭОТАР-Медиа; 2009. 422 с.

5. Rapoport B, McLachlan SM. TSH receptor cleavage into subunits and shedding of the Asubunit; a molecular and clinical perspective. Endocr Rev. 2016; 37: 114 - 134. doi: 10.1210/er.2015-1098

6. Smith TJ, Hegedus L, Douglas RS. Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves' orbitopathy. Best Pract Res. Clin Endocrinol Metab. 2012; 26(3): 291 - 302. doi: 10.1016/j.beem.2011.10.002

7. Brix TH, Kyvik KO, Christensen K, Hegedus L: Evidence for a major role of heredity in Graves' disease: a population-based study of two Danish twin cohorts. J Clin Endocrinol Metab. 2001; 86: 930 - 934. doi: 10.1210/jcem.86.2.7242.

8. Inaba H, De Groot LJ, Akamizu T: Thyrotropin receptor epitope and human leukocyte antigen in Graves' disease. Front Endocrinol. 2016; 7: 120. doi: 10.3389/fendo.2016.00120.

9. Lee HJ, Li CW, Hammerstad SS, Stefan M, Tomer Y. Immunogenetics of autoimmune thyroid diseases: a comprehensive review. J Autoimmun. 2015; 64: 82 - 90. doi: 10.1016/j.jaut.2015.07.009.

10. Brix TH, Hansen PS, Kyvik KO, Hegedus L. Cigarette smoking and risk of clinically overt thyroid disease: a population-based twin case-control study. Arch Intern Med. 2000; 160: 661 - 666. doi: 10.1001/archinte.160.5.661.

11. Manji N, Carr-Smith JD, Boelaert K, et al. Influences of age, gender, smoking and family history on autoimmune thyroid disease phenotype. J Clin Endocrinol Metab. 2006; 91(12): 4873 - 4880. doi: 10.1210/jc.2006-1402.

12. Свириденко Н.Ю. Функциональная автономия при эндемическом зобе. Проблемы эндокринологии. 2005; 1: 40 - 42. doi: 10.14341/probl200551140-41

13. Gozu HI, Lublinghoff J, Bircan R, Paschke R. Genetics and phenomics of inherited and sporadic non-autoimmune hyperthyroidism. Mol Cell Endocrinol. 2010; 322: 125 - 134. doi: 10.1016/j.mce.2010.02.001

14. Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, Rivkees SA, Samuels M, Sosa JA, Stan MN, Walter MA. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016; 26(10): 1343 - 1421. doi: 10.1089/thy.2016.0229

15. Российская ассоциация эндокринологов. Национальные рекомендации: Тиреотоксикоз с диффузным зобом (диффузный токсический зоб, болезнь Грейвса-Базедова), узловым/многоузловым зобом. М.; 2014.

16. Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, Laurberg P, McDougall IR, Montori VM, Rivkees SA, Ross DS, Sosa JA, Stan MN. Hyperthyroidism and Other Causes of Thyrotoxicosis: Management Guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr. Pract. 2011; 17(3): 456 - 520. doi: 10.4158/ep.17.3.456

17. Nystrom HF, Jansson S, Berg G. Incidence rate and clinical features of hyperthyroidism in a long-term iodine sufficient area of Sweden (Gothenburg) 2003 - 2005. Clin Endocrinol. 2013; 78: 768 - 776. doi: 10.1111/cen.12060

18. McLeod DS, Caturegli P, Cooper DS, Matos PG, Hutfless S. Variation in rates of autoimmune thyroid disease by race/ethnicity in US military personnel. JAMA. 2014; 311: 1563 - 1565. doi: 10.1001/jama.2013.285606

19. Свириденко Н.Ю. Тиреотоксикоз. Национальное руководство "Общая врачебная практика"/под редакцией И.Н. Денисова, О.М. Лесняк. М.: ГЭОТАР-Медиа; 2013. С. 677 - 689.

20. van de Ven AC, Netea-Maier RT, de Vegt F, Ross HA, Sweep FC, Kiemeney LA, Smit JW, Hermus AR, den Heijer M. Associations between thyroid function and mortality: the influence of age. Eur J Endocrinol. 2014; 171(2): 183 - 191. doi: 10.1530/EJE-13-1070.

21. Asvold BO, Bjoro T, Platou C, Vatten LJ. Thyroid function and the risk of coronary heart disease: 12-year follow-up of the HUNT study in Norway. Clin Endocrinol (Oxf). 2012; 77: 911 - 917. doi: 10.1111/j.1365-2265.2012.04477.x.

22. Biondi B, Kahaly GJ. Cardiovascular involvement in patients with different causes of hyperthyroidism. Nat Rev Endocrinol. 2010; 6: 431 - 443. doi: 10.1038/nrendo.2010.105.

23. Selmer C, Olesen JB, Hansen ML, von Kappelgaard LM, Madsen JC, Hansen PR, Pedersen OD, Faber J, Torp-Pedersen C, Gislason GH. Subclinical and overt thyroid dysfunction and risk of all-cause mortality and cardiovascular events: a large population study. J Clin Endocrinol Metab. 2014; 99(7): 2372 - 2382. doi: 10.1210/jc.2013-4184

24. Дедов И.И., Калашников В.Ю., Терехин С.А., Головенко Е.Н., Свириденко Н.Ю., Мелкозеров К.В., Парфененкова А.А., Копылов Ф.Ю., Грибанова А.В. Фатальный спазм коронарной артерии у пациента с тиреотоксикозом. Кардиология. 2012; 52(11): 92 - 96. ISSN0022-9040

25. Свириденко Н.Ю., Тугеева Э.Ф., Арипов М.А., Бузиашвили Ю.И. Функциональный резерв сердца и показатели левого желудочка у больных диффузным токсическим зобом после медикаментозного восстановления эутиреоза тиамазолом. Проблемы эндокринологии. 2009; 55(3): 21 - 24. doi.10.14341/probl200955321-24

26. Арипов М.А., Свириденко Н.Ю., Тугеева Э.Ф., Бузиашвили Ю.И. Ремоделирование левого желудочка у больных тиреотоксикозом. Проблемы эндокринологии. 2009; 55(4): 11 - 15. doi.10.14341/probl200955411-15

27. Свириденко Н.Ю., Беловалова И.М., Шеремета М.С., Табеева К.И., Ремизов О.В. Болезнь Грейвса и эндокринная офтальмопатия/Под редакцией академика РАН И.И. Дедова и академика РАН Г.А. Мельниченко. М.: МАИ-ПРИНТ; 2012. 143 с.

28. Fadeyev V. Clinical Aspects of Thyroid Disorders in the Elderly Thyroid international. 2007; 3: 4 - 15.

29. Nanchen D, Gussekloo J, Westendorp RG, Stott DJ, Jukema JW, Trompet S, Ford I, Welsh P, Sattar N, Macfarlane PW, Mooijaart SP, Rodondi N, de Craen AJPROSPER Group. Subclinical thyroid dysfunction and the risk of heart failure in older persons at high cardiovascular risk. J Clin Endocrinol Metab. 2012: 97(3): 852 - 861. doi: 10.1210/jc.2011-1978.

30. Waring AC, Harrison S, Samuels MH, Ensrud KE, LeBLanc ES, Hoffman AR, Orwoll E, Fink HA, Barrett-Connor E, Bauer DC. Thyroid function and mortality in older men: a prospective study. J Clin Endocrinol Metab. 2012; 97(3): 862 - 870. doi: 10.1210/jc.2011-2684.

31. Ceresini G, Ceda GP, Lauretani F, Maggio M, Usberti E, Marina M, Bandinelli S, Guralnik JM, Valenti G, Ferrucci L. Thyroid status and 6-year mortality in elderly people living in a mildly iodine-deficient area: the aging in the Chianti Area Study. J Am Geriatr Soc. 2013; 61: 868 - 874.

32. Segna D, M, Limacher A, Baumgartner C, Blum MR, Beer JH, Kucher N, Righini M, Matter CM, Frauchiger B, Cornuz J, Aschwanden M, Banyai M, Osterwalder J, Husmann M, Egloff M, Staub D, B, Angelillo-Scherrer A, Aujesky D, Rodondi N. Association between thyroid dysfunction and venous thromboembolism in the elderly: a prospective cohort study. J Thromb Haemost. 2016 Apr; 14(4): 685 - 94. doi: 10.1111/jth.13276

33. Sohn SY, Lee E, Lee MK, Lee JH. The Association of Overt and Subclinical Hyperthyroidism with the Risk of Cardiovascular Events and Cardiovascular Mortality: Meta-Analysis and Systematic Review of Cohort Studies. Endocrinol Metab (Seoul). 2020; 35(4): 786 - 800. doi: 10.3803/EnM.2020.728

34. Blum MR, Bauer DC, Collet TH, Fink HA, Cappola AR, da Costa BR, Wirth CD, Peeters RP, Asvold BO, den Elzen WP, Luben RN, Imaizumi M, Bremner AP, Gogakos A, Eastell R, Kearney PM, Strotmeyer ES, Wallace ER, Hoff M, Ceresini G, Rivadeneira F, Uitterlinden AG, Stott DJ, Westendorp RG, Khaw KT, Langhammer A, Ferrucci L, Gussekloo J, Williams GR, Walsh JP, Juni P, Aujesky D, Rodondi N, Thyroid Studies Collaboration. Subclinical thyroid dysfunction and fracture risk: a meta-analysis. JAMA. 2015; 313(20): 2055 - 2065. doi: 10.1001/jama.2015.5161.

35. Chaker L, Baumgartner C, Ikram MA, Dehghan A, Medici M, Visser WE, Hofman A, Rodondi N, Peeters RP, Franco OH. Subclinical thyroid dysfunction and the risk of stroke: a systematic review and meta-analysis. Eur J Epidemiol. 2014; 29(11): 791 - 800. doi: 10.1007/s10654-014-9946-8.

36. Bartalena L. Diagnosis and management of Graves disease: a global overview. Nat Rev Endocrinol. 2013; 9(12): 724 - 734. doi: 10.1038/nrendo.2013.193.

37. Grebe SK, Kahaly GJ. Laboratory testing in hyperthyroidism. Am J Med. 2012; 125(9): S2. doi: 10.1016/j.amjmed.2012.05.013.

38. Bartalena L, Burch HB, Burman KD, Kahaly GJ. A 2013 European survey of clinical practice patterns in the management of Graves'disease. Clin Endocrinol. 2016; 84(1): 115 - 120. doi: 10.1111/cen.12688.

39. Smith TJ, Hegedus LN. Graves' disease. Engl J Med. 2016; 375(16): 1552 - 1565. doi: 10.1056/NEJMra1510030

40. Kahaly GJ, Olivo PD. Graves' disease. N Engl J Med. 2017; 376(2): 184. doi: 10.1056/NEJMc1614624.

41. Tozzoli R, Bagnasco M, Giavarina D, Bizzaro N. TSH receptor autoantibody immunoassay in patients with Graves' disease: improvement of diagnostic accuracy over different generations of methods: systematic review and meta-analysis. Autoimmun Rev. 2012; 12(2): 107 - 113. doi: 10.1016/j.autrev.2012.07.003.

42. Kahaly GJ, Diana T. TSH receptor antibody functionality and nomenclature. Front Endocrinol. 2017; 8: 28. doi: 10.3389/fendo.2017.00028.

43. Ponto KA, Kanitz M, Olivo PD, Pitz S, Pfeiffer N, Kahaly GJ. Clinical relevance of thyroidstimulating immunoglobulins in graves'ophthalmopathy. Ophthalmology. 2011; 118 (11): 2279 - 2285. doi: 10.1016/j.ophtha.2011.03.030.

44. Ponto KA, Diana T, Binder H, Matheis N, Pitz S, Pfeiffer N, Kahaly GJ. Thyroid-stimulating immunoglobulins indicate the onset of dysthyroid optic neuropathy. J Endocrinol Invest. 2015; 38(7): 769 - 777. doi: 10.1007/s40618-015-0254-2

45. Kampmann E, Diana T, Kanitz M, Hoppe D, Kahaly GJ. Thyroid stimulating but not blocking autoantibodies are highly prevalent in severe and active thyroid-associated orbitopathy: a prospective study. Int J Endocrinol. 2015; 2015: 678194. doi: 10.1155/2015/678194.

46. Kiefer FW, Klebermass-Schrehof K, Steiner M, Worda C, Kasprian G, Diana T, Kahaly GJ, Gessl A. Fetal/neonatal thyrotoxicosis in a newborn from a hypothyroid woman with Hashimoto thyroiditis. J Clin Endocrinol Metab. 2017; 102(1): 6 - 9. doi: 10.1210/jc.2016-2999.

47. Goichot B, Bouee S, Castello-Bridoux C, Caron P: Survey of clinical practice patterns in the management of 992 hyperthyroid patients in France. Eur Thyroid J. 2017; 6(3): 152 - 159. doi: 10.1159/000453260

48. Hegedus L. Thyroid ultrasound. Endocrinol Metab Clin North Am. 2001; 30(2): 339 - 360. doi: 10.1016/s0889-8529(05)70190-0.

49. Erdogan MF, Anil C, Cesur M, Baskal N, Erdogan G. Color flow Doppler sonography for the etiologic diagnosis of hyperthyroidism. Thyroid. 2007; 17(3): 223 - 228. doi: 10.1089/thy.2006.0104.

50. Ralls PW, Mayekawa DS, Lee KP, Colletti PM, Radin DR, Boswell WD, Halls JM. Color-flow Doppler sonography in Graves disease: thyroid inferno. AJR Am J Roentgenol. 1988; 150(4): 781 - 784. doi: 10.2214/ajr.150.4.781.

51. Kim TK, Lee EJ: The value of the mean peak systolic velocity of the superior thyroidal artery in the differential diagnosis of thyrotoxicosis. Ultrasonography. 2015; 34(4): 292 - 296. doi: 10.14366/usg.14059

52. Bogazzi F, Vitti P. Could improved ultrasound and power Doppler replace thyroidal radioiodine uptake to assess thyroid disease? Nat Clin Pract Endocrinol Metab. 2008; 4(2): 70 - 71. doi: 10.1038/ncpendmet0692.

53. Kahaly GJ, Bartalena L, Hegedus L, Leenhardt L., Poppe K., Pearce S.H. 2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism. European Thyroid Journal. 2018; 7(4): 167 - 186. DOI: https: /doi.org/10.1159/000490384

54. Kwak JY, Han KH, Yoon JH, Moon HJ, Son EJ, Park SH, Jung HK, Choi JS, Kim BM, Kim EK. Thyroid Imaging Reporting and Data System for US Features of Nodules: A Step in Establishing Better Stratification of Cancer Risk. Radiology. 2011; 260(3): 892 - 899. doi: 10.1148/radiol.11110206

55. Wang J, Zhang R Evaluation of 99mTc-MIBI in thyroid gland imaging for the diagnosis of amiodarone-induced thyrotoxicosis. Br J Radiol. 2017 Mar; 90(1071): 20160836. doi: 10.1259/bjr.20160836

56. Свириденко Н.Ю., Платонова Н.М., Молашенко Н.В., Голицин С.П., Бакалов С.А., Сердюк С.Е. Эндокринные аспекты применения амиодарона в клинической практике. (Алгоритм наблюдения и лечения функциональных расстройств щитовидной железы). Российский кардиологический журнал. 2012; 2(94): 63 - 71.

57. Бельцевич Д.Г., Ванушко В.Э., Мельниченко Г.А., Румянцев П.О., Фадеев В.В. Клинические рекомендации Российской ассоциации эндокринологов по диагностике и лечению (много) узлового зоба у взрослых. Эндокринная хирургия. 2016; 10(1): 5 - 12. doi: 10.14341/serg201615-12

58. Yang J, Zhu YJ, Zhong JJ, Zhang J, Weng WW, Liu ZF, Xu Q, Dong MJ. Characteristics of antithyroid drug-induced agranulocytosis in patients with hyperthyroidism: a retrospective analysis of 114 cases in a single institution in China involving 9690 patients referred for radioiodine treatment over 15 years. Thyroid. 2016(5); 26: 627 - 633. doi: 10.1089/thy.2015.0439.

59. Watanabe N, Narimatsu H, Noh JY, Yamaguchi T, Kobayashi K, Kami M, Kunii Y, Mukasa K, Ito K, Ito K. Antithyroid drug-induced hematopoietic damage: a retrospective cohort study of agranulocytosis and pancytopenia involving 50,385 patients with Graves'disease. J Clin Endocrinol Metab. 2012; 97(1): E49 - E53. doi: 10.1210/jc.2011-2221.

60. Pearce SH. Spontaneous reporting of adverse reactions to carbimazole and propylthiouracil in the UK. Clin Endocrinol. 2004; 61(5): 589 - 594. doi: 10.1111/j.1365-2265.2004.02135.x.

61. Otsuka F, Noh JY, Chino T, Shimizu T, Mukasa K, Ito K, Ito K, Taniyama M. Hepatotoxicity and cutaneous reactions after antithyroid drug administration. Clin Endocrinol (Oxf). 2012; 77(2): 310 - 315. doi: 10.1111/j.1365-2265.2012.04365.x.

62. Свириденко Н.Ю., Колода Д.Е. Антитиреоидные средства. В кн.: Рациональная фармакотерапия заболеваний эндокринной системы и нарушения обмена веществ: Руководство для практикующих врачей/Под общ. ред. И.И. Дедова, Г.А. Мельниченко. М.: Литтерра, 2013. С. 85 - 90.

63. Laurberg P, Berman DC, Andersen S, Bulow Pedersen I: Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy. Thyroid. 2011; 21(9): 951 - 956. doi: 10.1089/thy.2011.0039.

64. Cooper DS. Antithyroid drugs in the management of patients with Graves' disease: an evidence-based approach to therapeutic controversies. J Clin Endocrinol Metab. 2003; 88(8): 3474 - 3481. doi: 10.1210/jc.2003-030185.

65. Emiliano AB, Governale L, Parks M, Cooper DS. Shifts in propylthiouracil and methimazole prescribing practices: antithyroid drug use in the United States from 1991 to 2008. J Clin Endocrinol Metab. 2010; 95(5): 2227 - 2233. doi: 10.1210/jc.2009-2752.

66. Corvilain B, Hamy A., Brunaud L., Borson-Chazot F., Jacques Orgiazzi J., Hachmi LB., Semrouni M., Patrice Rodien P., Lepeutre C. Treatment of adult Graves' disease. Ann Endocrinol (Paris) (2018). doi.org/10.1016/j.ando.2018.08.003

67. Brito JP, Schilz S, Singh Ospina N, Rodriguez-Gutierrez R, Maraka S, Sangaralingham LR, Montori VM. Antithyroid drugs - the most common treatment for Graves' disease in the United States: a nationwide population-based study. Thyroid. 2016; 26(8): 1144 - 1145. doi: 10.1089/thy.2016.0222.

68. Hallberg P, Eriksson N, Ibanez L, Bondon-Guitton E, Kreutz R, Carva-jal A, et al. Genetic variants associated with antithyroid drug-induced agranulocytosis: a genome-wide association study in a European population. Lancet Diabetes Endocrinol. 2016; 4: 507 - 16.

69. Cooper DS. Antithyroid drugs. N Engl J Med. 2005; 3: 352(9): 905 - 917. doi: 10.1056/NEJMra042972.

70. Rivkees SA, Mattison DR. Ending propylthiouracil-induced liver failure in children. N Engl J Med. 2009; 360(15): 1574 - 1575. doi: 10.1056/NEJMc0809750.

71. Wang MT, Lee WJ, Huang TY, Chu CL, Hsieh CH. Antithyroid drug-related hepatotoxicity in hyperthyroidism patients: a populationbased cohort study. Br J Clin Pharmacol. 2014; 78(3): 619 - 629. doi: 10.1111/bcp.12336.

72. Nakamura H, Miyauchi A, Miyawaki N, Imagawa J. Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30 years in Japan. J Clin Endocrinol Metab. 2013; 98(12): 4776 - 4783. doi: 10.1210/jc.2013-2569

73. Yang J, Li LF, Xu Q, Zhang J, Weng WW, Zhu YJ, Dong MJ. Analysis of 90 cases of antithyroid drug-induced severe hepatotoxicity over 13 years in China. Thyroid. 2015; 25(3): 278 - 283. doi: 10.1089/thy.2014.0350.

74. Abraham P, Avenell A, McGeoch SC, Clark LF, Bevan JS. Antithyroid drug regimen for reating Graves' hyperthyroidism. Cochrane Database Syst Rev. 2010; 1: CD003420. doi: 10.1002/14651858.CD003420.pub4.

75. Sundaresh V, Brito JP, Wang Z, Prokop LJ, Stan MN, Murad MH, Bahn RS. Comparative effectiveness of therapies for Graves' hyperthyroidism: a systematic review and network meta-analysis. J Clin Endocrinol Metab. 2013; 98(9): 3671 - 3677. doi: 10.1210/jc.2013-1954.

76. Tagami T, Yambe Y, Tanaka T, Tanaka T, Ogo A, Yoshizumi H, Kaise K, Higashi K, Tanabe M, Shimazu S, Usui T, Shimatsu A, Naruse M. BBGD Study Group. Shortterm effects of beta-adrenergic antagonists and methimazole in new-onset thyrotoxicosis caused by Graves' disease. Intern Med. 2012; 51(17): 2285 - 2290. doi: 10.2169/internalmedicine.51.7302.

77. Biondi B, Fazio S, Carella C, Sabatini D, Amato G, Cittadini A, Bellastella A, Lombardi G, L. Control of adrenergic overactivity by beta-blockade improves the quality of life in patients receiving long term suppressive therapy with levothyroxine. J Clin Endocrinol Metab. 1994 May; 78(5): 1028 - 33. doi: 10.1210/jcem.78.5.8175955

78. Struja T, Fehlberg H, Kutz A, Guebelin L, Degen C, Mueller B, Schuetz P. Can we predict relapse in Graves' disease? Results from a systematic review and meta-analysis. Eur J Endocrinol. 2017; 176: 87 - 97.

79. Vos XG, Endert E, Zwinderman AH, Tijssen JG, Wiersinga WM: Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves' hyperthyroidism. J Clin Endocrinol Metab. 2016; 101: 1381 - 1389.

80. Diana T, Krause J, Olivo PD, Konig J, Kanitz M, Decallonne B, Kahaly GJ: Prevalence and clinical relevance of thyroid stimulating hormone receptor-blocking antibodies in autoimmune thyroid disease. Clin Exp Immunol. 2017; 189: 304 - 309.

81. Diana T, Wьster C, Olivo PD, Unterrainer A, Kцnig J, Kanitz M, Bossowski A, Decallonne B, Kahaly GJ: Performance and specificity of six immunoassays for TSH receptor antibodies: a multicenter study. Eur Thyroid J. 2017; 6: 2.

82. Villagelin D, Romaldini JH, Santos RB, Milkos AB, Ward LS: Outcomes in relapsed Graves' disease patients following radioiodine or prolonged low dose of methimazole treatment. Thyroid. 2015; 25: 12821290.

83. Azizi F, Ataie L, Hedayati M, Mehrabi Y, Sheikholeslami F. Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine. Eur J Endocrinol. 2005; 152: 695 - 701.

84. Donovan PJ, McLeod DS, Little R, Gordon L. Cost-utility analysis comparing radioactive iodine, anti-thyroid drugs and total thyroidectomy for primary treatment of Graves' disease. Eur J Endocrinol. 2016; 175(6): 595 - 603. doi: 10.1530/EJE-16-0527.

85. Фомин Д.К., Свириденко Н.Ю., Румянцев П.О. Терапия радиоактивным йодом. В кн.: Национальное руководство: Эндокринология/Под ред. И.И. Дедова, Г.А. Мельниченко. М.: ГЭОТАР-Медиа, 2016. С. 381 - 390.

86. ICRP, 2000. Pregnancy and Medical Radiation. ICRP Publication 84. Ann. ICRP 30 (1).

87. Meier DA, Brill DR, Becker DV, Clarke SE, Silberstein EB, Royal HD, Balon HR; Society of Nuclear Medicine. Procedure guideline for therapy of thyroid disease with (131)iodine. J Nucl Med. 2002 Jun; 43(6): 856 - 61. PMID: 12050333.

88. Kravets I. Hyperthyroidism: Diagnosis and Treatment. Am Fam Physician. 2016 Mar 1; 93(5): 363 - 70. PMID: 26926973.

89. American Thyroid Association Taskforce On Radioiodine Safety, Sisson JC, Freitas J, McDougall IR, Dauer LT, Hurley JR, Brierley JD, Edinboro CH, Rosenthal D, Thomas MJ, Wexler JA, Asamoah E, Avram AM, Milas M, Greenlee C. Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I: practice recommendations of the American Thyroid Association. Thyroid. 2011 Apr; 21(4): 335 - 46. doi: 10.1089/thy.2010.0403.

90. Berg GE, EH, Jacobsson L, Lindberg S, Lindstedt RG, Mattsson S, Niklasson CA, AH, Westphal OG. Radioiodine treatment of hyperthyroidism in a pregnant women. J Nucl Med. 1998; 39(2): 357 - 361. PMID: 9476950.

91. Sawka AM, Lakra DC, Lea J, Alshehri B, Tsang RW, Brierley JD, Straus S, Thabane L, Gafni A, Ezzat S, George SR, Goldstein DP. A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors. Clin Endocrinol (Oxf). 2008; 69(3): 479 - 90. doi: 10.1111/j.1365-2265.2008.03222.x.

92. Silberstein EB, Alavi A, Balon HR, Clarke SE, Divgi C, Gelfand MJ, Goldsmith SJ, Jadvar H, Marcus CS, Martin WH, Parker JA, Royal HD, Sarkar SD, Stabin M, Waxman AD. The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. J Nucl Med. 2012 Oct; 53(10): 1633 - 51. doi: 10.2967/jnumed.112.105148. Epub 2012 Jul 11. PMID: 22787108.

93. Ross D.S. (2015) Radioiodine Treatment in Patients with Graves' Disease. In: Bahn R. (eds) Graves' Disease. Springer, New York, NY. https: //doi.org/10.1007/978-1-4939-2534-6_7

94. Iakovou, I., Giannoula, E., Exadaktylou, P., & Papadopoulos, N. (2021). RAI Therapy for Graves' Hyperthyroidism. In (Ed.), Graves' Disease. IntechOpen. https://doi.org/10.5772/intechopen.96083.

95. Stan MN, Durski JM, Brito JP, Bhagra S, Thapa P, Bahn RS. Cohort study on radioactive iodine-induced hypothyroidism: implications for Graves' ophthalmopathy and optimal timing for thyroid hormone assessment. Thyroid. 2013; 23(5): 620 - 625. doi: 10.1089/thy.2012.0258.

96. Nygaard B, L, Gervil M, Hjalgrim H, Hansen BM, P, Hansen JM. Influence of compensated radioiodine therapy on thyroid volume and incidence of hypothyroidism in Graves' disease. J Intern Med. 1995; 238(6): 491 - 497. doi: 10.1111/j.1365-2796.1995.tb01230.x.

97. Sridama V, McCormick M, Kaplan EL, Fauchet R, DeGroot LJ. Long-term follow-up study of compensated low-dose 131I therapy for Graves' disease. N Engl J Med. 1984; 16: 311(7): 426 - 32. doi: 10.1056/NEJM198408163110702.

98. Фадеев В.В., Дроздовский Б.Я., Гусева Т.Н., Гарбузов П.И., Бузиашвили И.И., Мельниченко Г.А. Отдаленные результаты лечения токсического зоба радиоактивным 131I. Проблемы эндокринологии. 2005; 51(1): 3 - 9. doi.org/10.14341/probl20055113-9.

99. Esfahani AF, Kakhki VR, Fallahi B, Eftekhari M, Beiki D, Saghari M, Takavar A. Comparative evaluation of two fixed doses of 185 and 370 MBq 131I, for the treatment of Graves' disease resistant to antithyroid drugs. Hell J. Nucl. Med. 2005; 8(3): 158 - 161. PMID: 16390021.

100. Bonnema SJ, L. Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. Endocr Rev. 2012; 33(6): 920 - 80. doi: 10.1210/er.2012-1030.

101. Walter MA, Briel M, Christ-Crain M, Bonnema SJ, Connell J, Cooper DS, Bucher HC, J, B. Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. BMJ. 2007; 334(7592): 514. doi: 10.1136/bmj.39114.670150.BE.

102. Burch HB, Solomon BL, Cooper DS, Ferguson P, Walpert N, Howard R. The effect of antithyroid drug pretreatment on acute changes in thyroid hormone levels after (131)I ablation for Graves' disease. J Clin Endocrinol Metab. 2001 Jul; 86(7): 3016 - 21. doi: 10.1210/jcem.86.7.7639. PMID: 11443161.]

103. Andrade VA, Gross JL, Maia AL. Effect of methimazole pretreatment on serum thyroid hormone levels after radioactive treatment in Graves' hyperthyroidism. J Clin Endocrinol Metab. 1999; 84(11): 4012 - 4016. doi: 10.1210/jcem.84.11.6149.

104. Bonnema SJ, Bennedbaek FN, Gram J, Veje A, Marving J, Hegedus L. Resumption of methimazole after 131I therapy of hyperthyroid diseases: effect on thyroid function and volume evaluated by a randomized clinical trial. Eur J Endocrinol. 2003; 149(6): 485 - 492. doi: 10.1530/eje.0.1490485.

105. Bartalena L, Tanda ML, Piantanida E, Lai A. Glucocorticoids and outcome of radioactive iodine therapy for Graves' hyperthyroidism. Eur J Endocrinol. 2005; 153(1): 13 - 14. doi: 10.1530/eje.1.01938.

106. Lillevang-Johansen M, Abrahamsen B, HL, Brix TH, L. Excess Mortality in Treated and Untreated Hyperthyroidism Is Related to Cumulative Periods of Low Serum TSH. J Clin Endocrinol Metab. 2017; 1: 102(7): 2301 - 2309. doi: 10.1210/jc.2017-00166.

107. Corvilain B, Hamy A, Brunaud L, Borson-Chazot F, Orgiazzi J, Hachmi LB, Semrouni M, Rodien P, Lepeutre C. Consensus. Treatment of adult Graves' disease. 2018. Annales d'Endocrinologie. https: /doi.org/10.1016/j.ando.2018.08.003

108. Edafe O, Antakia R, Laskar N, Uttley L, Balasubramanian SP. Systematic review and meta-analysis of predictors of post-thyroidectomy hypocalcaemia. Br J Surg. 2014; 101(4): 307 - 320. doi: 10.1002/bjs.9384.

109. Guo Z, Yu P, Liu Z, Si Y, Jin M: Total thyroidectomy vs bilateral subtotal thyroidectomy in patients with Graves' diseases: a meta-analysis of randomized clinical trials. Clin Endocrinol. 2013; 79(5): 739 - 746. doi: 10.1111/cen.12209.

110. Sosa JA, Bowman HM, Tielsch JM, Powe NR, Gordon TA, Udelsman R. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg. 2008; 228(3): 320 - 330. doi: 10.1097/00000658 - 199809000-00005.

111. Genovese BM, Noureldine SI, Gleeson EM, Tufano RP, Kandil E. What is the best definitive treatment for Graves' disease? A systematic review of the existing literature. Ann Surg Oncol. 2013; 20(2): 660 - 667. doi: 10.1245/s10434-012-2606-x.

112. Piantanida E. Preoperative management in patients with Graves' disease. Gland Surg. 2017 Oct; 6(5): 476 - 481. doi: 10.21037/gs.2017.05.09

113. Трошина Е.А., Свириденко Н.Ю., Ванушко В.Э., Румянцев П.О., Фадеев В.В., Петунина Н.А. Федеральные клинические рекомендации по диагностике и лечению токсического зоба. Проблемы Эндокринологии. 2014; 60(6): 67 - 77. https: /doi.org/10.14341/probl201460667-77

114. Krassas GE, Poppe K, Glinoer D. Thyroid function and human reproductive health. Endocr Rev. 2010; 31(5): 702 - 755. doi: 10.1210/er.2009-0041.

115. Andersen SL, Olsen J, Laurberg P. Antithyroid drug side effects in the population and in pregnancy. J Clin Endocrinol Metab. 2016; 101(4): 1606 - 1614. doi: 10.1210/jc.2015-4274.

116. Andersen SL, Olsen J, Laurberg P. Maternal thyroid disease in the Danish National Birth Cohort: prevalence and risk factors. Eur J Endocrinol. 2016; 174(2): 203 - 212. doi: 10.1530/EJE-15-0816.

117. Li H, Zheng J, Luo J, Zeng R, Feng N, Zhu N, Feng O. Congenital anomalies in children exposed to antithyroid drugs in-utero: a meta-analysis of cohort studies. PloS One. 2015; 10(5): e0126610. doi: 10.1371/journal.pone.0126610.

118. Yoshihara Noh JY, Watanabe Fukushita M, Matsumoto M, Suzuki N, Hoshiyama A, Suzuki A, Mitsumatsu T, Kinoshita A, Kentaro Mikura K, Yoshimura R, Sugino K, Ito K. Exposure to Propylthiouracil in the First Trimester of Pregnancy and Birth Defects: A Study at a Single Institution. J Endocr Soc. 2021; 19; 5(3): 204. doi: 10.1210/jendso/bvaa204.

119. Эндокринные заболевания и беременность в вопросах и ответах. Руководство для врачей/под ред. И.И. Дедова, Г.А. Мельниченко, Ф.Ф. Бурумкуловой. Москва.: Е-ното, 2024. 336 с. ISBN 978-5-906023-36-0

120. Cooper DS, Laurberg P. Hyperthyroidism in pregnancy. Lancet Diabetes Endocrinol. 2013; 1(3): 238 - 249. doi: 10.1016/S2213-8587(13)70086-X.

121. Soldin OP, Tractenberg RE, Hollowell JG, Jonklaas J, Janicic N, Soldin SJ. changes in maternal thyroid hormone, thyrotropin, and thyroglobulin concentrations during gestation: trends and associations across trimesters in iodine . Thyroid. 2004; 14(12): 1084 - 1090. doi: 10.1089/thy.2004.14.1084.

122. Lo JC, Rivkees SA, Chandra M, Gonzalez JR, Korelitz JJ, Kuzniewicz MW. Gestational thyrotoxicosis, antithyroid drug use and neonatal outcomes within an integrated healthcare delivery system. Thyroid. 2015; 25(6): 698 - 705. doi: 10.1089/thy.2014.0434.

123. Andersen SL, Olsen J, Carle A, Laurberg P. Hyperthyroidism incidence fluctuates widely in and around pregnancy and is at variance with some other autoimmune diseases: a Danish population-based study. J Clin Endocrinol Metab. 2015; 100(3): 1164 - 1171. doi: 10.1210/jc.2014-3588.

124. Grebe SK, Kahaly GJ. Laboratory testing in hyperthyroidism. Am J Med. 2012; 125(9): S2. doi: 10.1016/j.amjmed.2012.05.013.

125. Bartalena L, Burch HB, Burman KD, Kahaly GJ. A 2013 European survey of clinical practice patterns in the management of Graves'disease. Clin Endocrinol. 2016; 84(1): 115 - 120. doi: 10.1111/cen.12688.

126. Kahaly GJ, Olivo PD. Graves' disease. N Engl J Med. 2017; 376(2): 184. doi: 10.1056/NEJMc1614624.

127. McKenzie JM, Zakarija M. Fetal and neonatal hyperthyroidism and hypothyroidism due to maternal TSH receptor antibodies. Thyroid. 1992; 2(2): 155 - 159. doi: 10.1089/thy.1992.2.155.

128. Abeillon-du Payrat J, Chikh K, Bossard N, Bretones P, Gaucherand P, Claris O, Charrie A, Raverot V, Orgiazzi J, Borson-Chazot F, Bournaud C. Predictive value of maternal second-generation thyroid-binding inhibitory immunoglobulin assay for neonatal autoimmune hyperthyroidism. Eur J Endocrinol. 2014; 171(4): 451 - 460. doi: 10.1530/EJE-14-0254.

129. Nakamura H, Noh JY, Itoh K, Fukata S, Miyauchi A, Hamada N: Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves'disease. J Clin Endocrinol. Metab. 2007; 92: 2157 - 2162.

130. Yoshihara A, Noh J, Yamaguchi T, Ohye H, Sato S, Sekiya K, Kosuga Y, Suzuki M, Matsumoto M, Kunii Y, Watanabe N, Mukasa K, Ito K, Ito K. Treatment of Graves' disease with antithyroid drugs in the first trimester of pregnancy and the prevalence of congenital malformation. J Clin Endocrinol Metab. 2012; 97: 2396 - 2403.

131. Andersen SL, Olsen J, Laurberg P. Antithyroid drug side effects in the population and in pregnancy. J Clin Endocrinol Metab. 2016; 101: 1606 - 1614.

132. Andersen SL, L, Olsen J, Vestergaard P, Andersen S. Maternal thyroid function, use of antithyroid drugs in early pregnancy, and birth defects. J Clin Endocrinol Metab. 2019; 104(12): 6040 - 6048. doi: 10.1210/jc.2019-01343.

133. Seo GH, Kim TH, Chung JH. Antithyroid drugs and congenital malformations: a nationwide Korean cohort study. Ann Intern Med. 2018; 168(6): 405 - 413. doi: 10.7326/M17-1398.

134. Li H, Zheng J, Luo J, Zeng R, Feng N, Zhu N, Feng O. Congenital anomalies in children exposed to antithyroid drugs in-utero: a meta-analysis of cohort studies. PloS One. 2015; 10(5): e0126610. doi: 10.1371/journal.pone.0126610.

135. Andersen SL, Olsen J, Wu CS, Laurberg P. Severity of birth defects after propylthiouracil exposure in early pregnancy. Thyroid. 2014; 24(10): 1533 - 1540. doi: 10.1089/thy.2014.0150.

136. Laurberg P, Andersen SL. Therapy of endocrine disease: antithyroid drug use in early pregnancy and birth defects: time windows of relative safety and high risk? Eur J Endocrinol. 2014; 171(1): 13 - R20. doi: 10.1530/EJE-14-0135.

137. Korelitz JJ, McNally DL, Masters MN, Li SX, Xu Y, Rivkees SA. Prevalence of thyrotoxicosis, antithyroid medication use, and complications among pregnant women in the United States. Thyroid. 2013; 23(6): 758 - 765. doi: 10.1089/thy.2012.0488.

138. Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C, Grobman WA, Laurberg P, Lazarus JH, Mandel SJ, Peeters RP, Sullivan S. 2017 guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid. 2017; 27(3): 315 - 389. doi: 10.1089/thy.2016.0457.

139. Rubin PC. Current concepts: beta-blockers in pregnancy. N Engl J Med. 1981; 305(22): 1323 - 1326. doi: 10.1056/NEJM198111263052205.

140. Laurberg P, Bournaud C, Karmisholt J, Orgiazzi J. Management of Graves' hyperthyroidism in pregnancy: focus on both maternal and foetal thyroid function, and caution against surgical thyroidectomy in pregnancy. Eur J Endocrinol. 2009; 160(1): 1 - 8. doi: 10.1530/EJE-08-0663.

141. Sawka AM, Lakra DC, Lea J, Alshehri B, Tsang RW, Brierley JD, Straus S, Thabane L, Gafni A, Ezzat S, George SR, Goldstein. A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors. Clin Endocrinol. 2008; 69(3): 479 - 490. doi: 10.1111/j.1365-2265.2008.03222.x

142. Tran P, Desimone S, Barrett M, Bachrach B. I-131 treatment of graves' disease in an unsuspected first trimester pregnancy; the potential for adverse effects on the fetus and a review of the current guidelines for pregnancy screening. Int J Pediatr Endocrinol. 2010; 2010: 858359. doi: 10.1155/2010/858359.

143. Nedrebo BG, Holm PI, Uhlving S, Sorheim JI, Skeie S, Eide GE, Husebye ES, Lien EA, Aanderud S. Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves' disease. Eur J Endocrinol. 2002; 147(5): 583 - 589. doi: 10.1530/eje.0.1470583.

144. Laurberg P/Remission of Graves' disease during anti-thyroid drug therapy: time to reconsider the mechanism? Eur J Endocrinol. 2006; 155(6): 783 - 786. doi: 10.1530/eje.1.02295.

145. Mandel SJ, Cooper DS. The use of antithyroid drugs in pregnancy and lactation. J Clin Endocrinol Metab. 2001; 86(6): 2354 - 2359. doi: 10.1210/jcem.86.6.7573.

146. Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell'Unto E, Bruno-Bossio G, Nardi M, Bartolomei MP, Lepri A, Rossi G, Martino E, Pinchera A. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med. 1998; 338: 73 - 78. doi: 10.1056/NEJM199801083380201.

147. Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren JG, Blomgren H, Taube A. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. N Engl J Med. 1992; 326: 1733 - 1738. doi: 10.1056/NEJM199206253262603.

148. Bartalena L. The dilemma of how to manage Graves' hyperthyroidism in patients with associated orbitopathy. J Clin Endocrinol Metab. 2011; 96: 592 - 599. doi: 10.1210/jc.2010-2329.

149. Табеева К.И. Клиническое течение эндокринной офтальмопатии после хирургического лечения болезни Грейвса. Дисс.... к-та мед. наук. М.$ 2010. С 51 - 69.

150. Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Torring O. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol. 2008; 158: 69 - 75. DOI: 10.1530/EJE-07-0450.

151. Chen DY., Schneider PF., Zhang XS., Luo XY, He ZM, Chen TH. Changes in graves' ophthalmopathy after radioiodine and anti-thyroid drug treatment of Graves' disease from 2 prospective, randomized, open-label, blinded end point studies. Exp Clin Endocrinol Diabetes. 2014; 122(1): 1 - 6. doi: 10.1055/s-0033-1358484.

152. Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM. European Group on Graves Orbitopathy: The 2016 European Thyroid Association/European Group on Graves' Orbitopathy guidelines for the management of Graves' orbitopathy. Eur Thyroid J. 2016; 5: 9 - 26. doi: 10.1159/000443828.

153. Tallstedt L, Lundell G, Blomgren H, Bring J. Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment? Eur J Endocrinol. 1994; 130: 494 - 497. doi: 10.1530/eje.0.1300494.

154. Karlsson F, Dahlberg P, Jansson R, Westermark K, Enoksson P. Importance of TSH receptor activation in the development of severe endocrine ophthalmopathy. Acta Endocrinol. 1989; 121(2): 132 - 141.

155. Bartalena L, Macchia PE, Marcocci C, Salvi M, Vermiglio F. Effects of treatment modalities for Graves' hyperthyroidism on Graves' orbitopathy: a 2015 Italian Society of Endocrinology Consensus Statement. J Endocrnol Invest. 2015; 38: 481 - 487. doi: 10.1007/s40618-015-0257-z.

156. Lai A, Sassi L, Compri E, Marino F, Sivelli P, Piantanida E, Tanda ML, Bartalena L. Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent Graves' orbitopathy: a retrospective cohort study. J Clin Endocrinol Metab. 2010; 95: 1333 - 1337. doi: 10.1210/jc.2009-2130.

157. Perros P, Kendall-Taylor P, Neoh C, Frewin S, Dickinson J. A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active Graves' ophthalmopathy. J Clin Endocrinol Metab. 2005; 90: 5321 - 5323. doi: 10.1210/jc.2005-0507.

158. Acharya SH, Avenell A, Philip S, Burr J, Bevan JS, Abraham P. Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy: a systematic review. Clin Endocrinol. 2008; 69: 943 - 950. doi: 10.1111/j.1365-2265.2008.03279.x.

159. Shiber S, Stiebel-Kalish H, Shimon I, Grossman A, Robenshtok E. Glucocorticoid regimens for prevention of Graves' ophthalmopathy progression following radioiodine treatment: systematic review and meta-analysis. Thyroid. 2014; 24: 1515 - 1523. doi: 10.1089/thy.2014.0218.

160. Bartalena L, Marcocci C, Bogazzi F, Panicucci M, Lepri A, Pinchera A. Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med. 1989; 321: 1349 - 1352. doi: 10.1056/NEJM198911163212001.

161. Traisk F, Tallstedt L, Abraham-Nordling M, Andersson T, Berg G, Calissendorff J, Hallengren B, Hedner P, Lantz M, Nystrom E, Ponjavic V, Taube A, Torring O, Wallin G, Asman P, Lundell G. Thyroid Study Group of TT 96: Thyroid-associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab. 2009; 94: 3700 - 3707. doi: 10.1210/jc.2009-0747.

162. Vannucchi G, Campi I, Covelli D, Dazzi D, Curro N, Simonetta S, Ratiglia R, Beck-Peccoz P, Salvi M. Graves' orbitopathy activation after radioactive iodine therapy with and without steroid prophylaxis. J Clin Endocrinol Metab. 2009; 94: 3381 - 3386. doi: 10.1210/jc.2009-0506.

163. Kung AW, Yau CC, Cheng A. The incidence of ophthalmopathy after radioiodine therapy for Graves' disease: prognostic factors and the role of methimazole. J Clin Endocrinol Metab. 1994; 79: 542 - 546. doi: 10.1210/jcem.79.2.7913934.

164. Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, M, Vaidya B, Wiersinga WM, EUGOGO. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. Eur J Endocrinol. 2021; 185(4): G43 - G67. doi: 10.1530/EJE-21-0479.

165. Marcocci C, Bruno-Bossio G, Manetti L, Tanda ML, Miccoli P, Iacconi P, Bartolomei MP, Nardi M, Pinchera A, Bartalena L. The course of Graves' ophthalmopathy is not influenced by near total thyroidectomy: a case-control study. Clin Endocrinol. 1999; 51: 503 - 508. doi: 10.1046/j.1365-2265.1999.00843.x.

166. Biondi B, Bartalena L, Cooper DS, Hegedus L, Laurberg P, Kahaly GJ. The 2015 European Thyroid Association guidelines on diagnosis and treatment of endogenous subclinical hyperthyroidism. Eur Thyroid J. 2015; 4(3): 149 - 163. doi: 10.1159/000438750.

167. Collet TH, Gussekloo J, Bauer DC, den Elzen WP, Cappola AR, Balmer P, Iervasi G, Asvold BO, Sgarbi JA, Volzke H, Gencer B, Maciel RM, Molinaro S, Bremner A, Luben RN, Maisonneuve P, Cornuz J, Newman AB, Khaw KT, Westendorp RG, Franklyn JA, Vittinghoff E, Walsh JP, Rodondi N. Thyroid Studies Collaboration: Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med. 2012; 172(10): 799 - 809. doi: 10.1001/archinternmed.2012.402.

168. Gencer B, Collet TH, Virgini V, Bauer DC, Gussekloo J, Cappola AR, Nanchen D, den Elzen WP, Balmer P, Luben RN, Iacoviello M, Triggiani V, Cornuz J, Newman AB, Khaw KT, Jukema JW, Westendorp RG, Vittinghoff E, Aujesky D, Rodondi N. Thyroid Studies Collaboration: Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts. Circulation. 2012; 126(9): 1040 - 1049. doi: 10.1161/CIRCULATIONAHA.112.096024.

169. Wirth CD, Blum MR, da Costa BR, Baumgartner C, Collet TH, Medici M, Peeters RP, Aujesky D, Bauer DC, Rodondi N. Subclinical thyroid dysfunction and the risk for fractures: a systematic review and meta-analysis. Ann Intern Med. 2014; 161(3): 189 - 199. doi: 10.7326/M14-0125.

170. Blum MR, Bauer DC, Collet TH, Fink HA, Cappola AR, da Costa BR, Wirth CD, Peeters RP, Asvold BO, den Elzen WP, Luben RN, Imaizumi M, Bremner AP, Gogakos A, Eastell R, Kearney PM, Strotmeyer ES, Wallace ER, Hoff M, Ceresini G, Rivadeneira F, Uitterlinden AG, Stott DJ, Westendorp RG, Khaw KT, Langhammer A, Ferrucci L, Gussekloo J, Williams GR, Walsh JP, Juni P, Aujesky D, Rodondi N. Thyroid Studies Collaboration: Subclinical thyroid dysfunction and fracture risk: a meta-analysis. JAMA. 2015; 313(20): 2055 - 2065. doi: 10.1001/jama.2015.5161.

171. Zhyzhneuskaya S, Addison C, Tsatlidis V, Weaver JU, Razvi S. The natural history of subclinical hyperthyroidism in Graves' disease: the rule of thirds. Thyroid. 2016; 26(6): 765 - 769. doi: 10.1089/thy.2015.0470.

172. Satoh T, Isozaki O, Suzuki A, Wakino S, Iburi T, Tsuboi K, Kanamoto N, Otani H, Furukawa Y, Teramukai S, Akamizu T. 2016 guidelines for the management of thyroid storm from the Japan Thyroid Association and Japan Endocrine Society (first edition). Endocr J. 2016; 63: 1025 - 1064. doi: 10.1507/endocrj.EJ16-0336.

173. Akamizu T. Thyroid storm: a Japanese perspective. Thyroid. 2018; 28: 32 - 40. doi: 10.1089/thy.2017.0243.

174. Burch HB, Wartofsky L. Life-threatening thyrotoxicosis: thyroid storm. Endocrinol Metab Clin North Am. 1993; 22: 263 - 277.

175. Akamizu T, Satoh T, Isozaki O, Suzuki A, Wakino S, Iburi T, Tsuboi K, Monden T, Kouki T, Otani H, Teramukai S, Uehara R, Nakamura Y, Nagai M, Mori M. Japan Thyroid Association: Diagnostic criteria, clinical features, and incidence of thyroid storm based on nationwide surveys. Thyroid. 2012; 22: 661 - 679. doi: 10.1089/thy.2011.0334

176. Isozaki O, Satoh T, Wakino S, Suzuki A, Iburi T, Tsuboi K, Kanamoto N, Otani H, Furukawa Y, Teramukai S, Akamizu T. Treatment and management of thyroid storm: analysis of the nationwide surveys: the taskforce committee of the Japan Thyroid Association and Japan Endocrine Society for the establishment of diagnostic criteria and nationwide surveys for thyroid storm. Clin Endocrinol. 2016; 84: 912 - 918. doi: 10.1111/cen.12949.

177. Brandt F, Thvilum M, Almind D, Christensen K, Green A, Hegedus L, Brix TH. Graves' disease and toxic nodular goiter are both associated with increased mortality but differ with respect to the cause of death: a Danish population-based register study. Thyroid. 2013; 23: 408 - 413. doi: 10.1089/thy.2012.0500

178. Erkan ME, Demirin H, Asik M, Celbek G, Yildirim M, Aydin Y, Gungor A, Dogan AS. Efficiency of radioactive I-131 therapy in geriatric patients with toxic nodular goiter. Aging Clin Exp Res. 2012; 24: 714 - 717. doi: 10.3275/8759

179. Kang AS, Grant CS, Thompson GB, van Heerden JA. 2002 Current treatment of nodular goiter with hyperthyroidism (Plummer's disease): surgery versus radioiodine. Surgery. 2002; 132: 916 - 923; discussion 923. doi: 10.1067/msy.2002.128691.

180. Porterfield JRJr, Thompson GB, Farley DR, Grant CS, Richards ML. Evidence-based management of toxic multinodular goiter (Plummer's disease). World J Surg. 2008; 32: 1278 - 1284. doi: 10.1007/s00268-008-9566-0.

181. Albino CC, Graf H, Sampaio AP, Vigario A, Paz-Filho GJ. Thiamazole as an adjuvant to radioiodine for volume reduction of multinodular goiter. Expert Opin Investig Drugs. 2008; 17: 1781 - 1786. doi: 10.1517/13543780802501325.

182. Gharib H, Papini E, Paschke R, Duick DS, Valcavi R, Hegedus L, Vitti P AACE/AME/ETA Task Force on Thyroid Nodules. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association Medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: executive summary of recommendations. Endocr Pract. 2010; 16: 468 - 475. doi: 10.4158/10024.GL.

183. Lee YY, Tam KW, Lin YM, Leu WJ, Chang JC, Hsiao CL, Hsu MT, Hsieh AT. Recombinant human thyrotropin before (131) I therapy in patients with nodular goitre: a meta-analysis of randomized controlled trials. Clin Endocrinol (Oxf). 2015; 83: 702 - 710. doi: 10.1210/jc.2004-1550.

184. Zakavi SR, Mousavi Z, Davachi B. Comparison of four different protocols of I-131 therapy for treating single toxic thyroid nodule. Nucl Med Commun. 2009; 30: 169 - 175. doi: 10.1097/MNM.0b013e3283169148.

185. Camargo R, Corigliano S, Friguglietti C, Gauna A, Harach R, Munizaga F, Niepomniszcze H, Pitoia F, Pretell E, Vaisman M, Ward LS, Wohllk N, Tomimori E. Latin American thyroid society. Latin American thyroid society recommendations for the management of thyroid nodules. Arq Bras Endocrinol Metabol. 2009; 53: 1167 - 1175. doi: 10.1590/s0004 - 27302009000900014.

186. Ceccarelli C, Bencivelli W, Vitti P, Grasso L, Pinchera A. Outcome of radioiodine-131 therapy in hyperfunctioning thyroid nodules: a 20 years' retrospective study. Clin Endocrinol (Oxf). 2005; 62: 331 - 335. doi.10.1111/j.1365-2265.2005.02218.x

187. Nygaard B, Hegedus L, Ulriksen P, Nielsen KG, Hansen JM. Radioiodine therapy for multinodular toxic goiter. Arch Intern Med. 1999; 159: 1364 - 1368. doi: 10.1001/archinte.159.12.1364.

188. Akbulut, A., Aydinbelge, F.N., & Koca, G. (2017). Radioiodine Treatment for Benign Thyroid Diseases. In (Ed.), Radionuclide Treatments. IntechOpen. https: //doi.org/10.5772/intechopen.68575

189. Vidal-Trecan GM, Stahl JE, Eckman MH. Radioiodine or surgery for toxic thyroid adenoma: dissecting an important decision. A cost-effectiveness analysis. Thyroid. 2004; 14: 933 - 945. doi: 10.1089/thy.2004.14.933.

190. Wahl RA, Rimpl I, Saalabian S, Schabram J. Differentiated operative therapy of thyroid autonomy (Plummer's disease). Exp Clin Endocrinol Diabetes. 1998; 4: 78 - 84.

191. Hisham AN, Azlina AF, Aina EN, Sarojah A. Total thyroidectomy: the procedure of choice for multinodular goitre. Eur J Surg. 2001; 167: 403 - 405.

192. Agarwal G, Aggarwal V. Is total thyroidectomy the surgical procedure of choice for benign multinodular goiter? An evidence-based review. World J Surg. 2008; 32(7): 1313 - 24. doi: 10.1007/s00268-008-9579-8.

193. Mishra A, Agarwal A, Agarwal G, Mishra SK. Total thyroidectomy for benign thyroid disorders in an endemic region. World J Surg. 2001; 25: 307 - 310. doi: 10.1007/s002680020100.

194. Stoll SJ, Pitt SC, Liu J, Schaefer S, Sippel RS, Chen H. Thyroid hormone replacement after thyroid lobectomy. Surgery. 2009; 146: 554 - 558; discussion 558 - 60. doi: 10.1016/j.surg.2009.06.026

195. Di Donna V, Santoro MG, de Waure C, Ricciato MP, Paragliola RM, Pontecorvi A, Corsello SM. 2014 A new strategy to estimate levothyroxine requirement after total thyroidectomy for benign thyroid disease. Thyroid. 2014 Dec; 24(12): 1759 - 64. doi: 10.1089/thy.2014.0111

196. Matte R, Ste-Marie LG, Comtois R, D'Amour P, Lacroix A, Chartrand R, Poisson R, Bastomsky CH. The pituitary-thyroid axis after hemithyroidectomy in euthyroid man. J Clin Endocrinol Metab. 1981; 53: 377 - 380. doi: 10.1210/jcem-53-2-377.

197. Thomusch O, Machens A, Sekulla C, Ukkat J, Lippert H, Gastinger I, Dralle H. Multivariate analysis of risk factors for postoperative complications in benign goiter surgery: prospective multicenter study in Germany. World J Surg. 2000; 24: 1335 - 1341. doi: 10.1007/s002680010221.

198. Takats KI, Szabolcs I, Foldes J, Foldes I, Ferencz A, Rimanoczy E, Goth M, Dohan O, Kovacs L, Szilagyi G. The efficacy of long term thyrostatic treatment in elderly patients with toxic nodular goitre compared to radioiodine therapy with different doses. Exp Clin Endocrinol Diabetes. 1999; 107: 70 - 74. doi: 10.1055/s-0029-1212076.

199. Мельниченко Г.А., Ларина И.И. Синдром тиреотоксикоза. Дифференциальная диагностика и лечение. Терапевтический архив. 2018; 90(10): 4 - 13. DOI: https: /doi.org/10.26442/terarkh201890104-13